Integrative Genomic–Epigenomic Analysis of Clozapine-Treated Patients with Refractory Psychosis
Mayén-Lobo YG, Martínez-Magaña JJ, Pérez-Aldana BE, Ortega-Vázquez A, Genis-Mendoza AD, de Montellano D, Soto-Reyes E, Nicolini H, López-López M, Monroy-Jaramillo N. Integrative Genomic–Epigenomic Analysis of Clozapine-Treated Patients with Refractory Psychosis. Pharmaceuticals 2021, 14: 118. PMID: 33557049, PMCID: PMC7913835, DOI: 10.3390/ph14020118.Peer-Reviewed Original ResearchRefractory psychosisPolygenic risk scoresMood stabilizersMetabolic ratioOnly antipsychotic drugUse of clozapineEffective mood stabilizerCLZ treatmentAntipsychotic drugsRisk scoreClozapineBipolar disorderLarger sample sizePatientsPsychosisGABAergic synapse pathwayBD-PRSFuture studiesSample sizeHigh-impact variantsAntipsychoticsPathwayFindingsMethylome profilesComplex mechanisms